Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -75.45% is 41% below its 5-year average of -53.59%, near the low end of its 5-year range (-102.21%–-6.22%).
21.18% below its 12-month average of -62.27%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -16.91%.
RETURN ON ASSETS (ROA)
-75.45%
RETURN ON ASSETS (ROA) AVG TTM
-62.27%
RETURN ON ASSETS (ROA) AVG 3Y
-65.14%
RETURN ON ASSETS (ROA) AVG 5Y
-53.59%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-21.18%
CURRENT VS 3Y AVG
-15.83%
CURRENT VS 5Y AVG
-40.79%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-133.84%
vs the sector median at left
Prime Medicine, Inc.
Market Cap
$632.16M
Return on Assets (ROA)
-75.45%
TTM Avg
-62.27%
3Y Avg
-65.14%
5Y Avg
-53.59%
Market Cap
$630.63M
Return on Assets (ROA)
-15.25%
TTM Avg
-20.29%
3Y Avg
-14.84%
5Y Avg
-12.37%
Market Cap
$634.30M
Return on Assets (ROA)
19.25%
TTM Avg
-15.00%
3Y Avg
-19.98%
5Y Avg
-33.37%
Market Cap
$638.20M
Return on Assets (ROA)
-37.63%
TTM Avg
-55.16%
3Y Avg
-41.63%
5Y Avg
-48.17%
Market Cap
$619.15M
Return on Assets (ROA)
-40.77%
TTM Avg
-44.28%
3Y Avg
-40.69%
5Y Avg
-35.92%
Market Cap
$611.57M
Return on Assets (ROA)
-23.40%
TTM Avg
-34.85%
3Y Avg
-33.75%
5Y Avg
-41.05%
Market Cap
$656.59M
Return on Assets (ROA)
-36.37%
TTM Avg
-26.71%
3Y Avg
-31.04%
5Y Avg
-27.33%
Market Cap
$657.89M
Return on Assets (ROA)
-20.36%
TTM Avg
-36.81%
3Y Avg
-36.81%
5Y Avg
-36.81%
Market Cap
$660.29M
Return on Assets (ROA)
-82.36%
TTM Avg
-56.97%
3Y Avg
-52.21%
5Y Avg
-45.34%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Prime Medicine, Inc. (PRME) | $632.16M | -75.45% | -62.27% | -65.14% | -53.59% |
| OmniAb, Inc. (OABI)vs › | $630.63M | -15.25% | -20.29% | -14.84% | -12.37% |
| Zevra Therapeutics, Inc. (ZVRA)vs › | $634.30M | 19.25% | -15.00% | -19.98% | -33.37% |
| Aura Biosciences, Inc. (AURA)vs › | $638.20M | -37.63% | -55.16% | -41.63% | -48.17% |
| SOPHiA GENETICS S.A. (SOPH)vs › | $619.15M | -40.77% | -44.28% | -40.69% | -35.92% |
| Climb Bio, Inc. (CLYM)vs › | $611.57M | -23.40% | -34.85% | -33.75% | -41.05% |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $656.59M | -36.37% | -26.71% | -31.04% | -27.33% |
| Starling Oncology, Inc. (STLN)vs › | $657.89M | -20.36% | -36.81% | -36.81% | -36.81% |
| Annexon, Inc. (ANNX)vs › | $660.29M | -82.36% | -56.97% | -52.21% | -45.34% |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $597.55M | 45.55% | 3.15% | -47.64% | -20.78% |
ROA
-75.5%
ROE
-472.0%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -58.69% |
| 2024-12-31 | -65.84% |
| 2023-12-31 | -102.21% |
| 2022-12-31 | -33.81% |
| 2021-12-31 | -54.78% |
| 2020-12-31 | -6.22% |
| 2019-12-31 | -29.08% |
